November - 20206NOVEMBER - 23 - 2020, volume 04 - Issue 20 (ISSN 2691-4093)Published by ValleyMedia, Inc. Managing EditorAlex D'souzaEditorial StaffVisualizerJohn GothamSalesAndrew D'Souzaandrew.dsouza@medicaltechoutlook.com510.996.5123Contact usEmailPhone:510 230 0396 Fax:510-894-8405sales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comJoshua Parker Merlin WatsonJoe Philip Laura PintoTo subscribe to MedicalTech OutlookVisit www.medicaltechoutlook.com Copyright © 2020 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffAlex D'souzaManaging Editoreditor@medicaltechoutlook.comScientific advances have revolutionized the treatment of many diseases. Previously acute or lethal conditions have come to be considered chronic as new treatments have led to longer life expectancies, and a lower rate of years lived with disability. These advances, however, come with rising costs in a resource-constrained environment. To achieve cost containment, reimbursement for IVDs is increasingly coming under pressure because they are perceived as a cost factor rather than a tool to reduce expenditure in the long term.Effectively used, IVDs help reduce hospital stays, support patients to look after their health, and release resources for use elsewhere in the NHS, resulting in a healthier population and substantial economic growth. Through molecular diagnostics, the industry also contributes to the natural evolution of medicine and more personalized treatment.With the future of healthcare focused on personalizing medicine and ensuring the right person gets the proper treatment at the right time, innovations in diagnostics will be critical to achieving this ambition. However, to make this a reality, the challenges preventing greater uptake and diffusion of diagnostic tests need to be addressed.Leafing through this special edition will allow strategic planners and practice leaders to comprehend the horizons of opportunity for translating trends into business profits. This edition also offers thought leadership from subject matter experts with real-life stories on fostering robust partnerships and exclusive insights from CXOs. We hope you get the right assistance in choosing the best in-vitro solution providers according to your requirements. Let us know your thoughts!In Vitro Diagnostics (IVD): Hope & Hype!Sarah FernandesEDITORIAL
< Page 5 | Page 7 >